Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Accendra Health, Inc.NYSE: ACH

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures turns positive

Q1 FY2026 capital expenditures was $72M, compared with -$64.67M a year earlier. Trailing-twelve-month capital expenditures was -$81.21M. Over 3 fiscal years it compounded at +6.5% a year.

Context

  • Capital expenditures amounted to 7.3% of revenue in FY2025, up 5.2 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near $72M or moves back toward the trailing-twelve-month quarterly average of -$20.3M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$72M+875.4% QoQ
Last fiscal yearDec 2025
-$201.33M-11.8% YoY
LTMMar 2026
-$81.21M-65.4% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+211.3%——
1 year-11.8%——
3-year CAGR+6.5%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(201.33M) USD
Year-over-year change
+11.8%

Capital Expenditures vs competitors

How ACH compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -65.4% is the 8th highest of 11, against a peer median of -50.4%.
  • Capital expenditures amounts to 3.0% of revenue for ACH, versus a peer median of 1.3%.
ACH Competitors
Capital Expenditures for ACH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACHAccendra Health, Inc.LTM Mar 2026$81.21M USD-65.4%+6.5%3.0%
HITIHigh Tide Inc.LTM Apr 2026CA$10.14M CAD-5.9%+5.5%1.5%
CGCCanopy Growth CorporationLTM Mar 2026CA$6.66M CAD-41.0%-10.7%2.1%
OMOutset Medical, Inc.LTM Mar 2026$740K USD+8.7%-54.2%0.6%
CVRXCVRx, Inc.LTM Mar 2026$588K USD+5.4%-5.4%1.0%
EDITEditas Medicine, Inc.LTM Mar 2026$585K USD-91.7%-47.2%1.5%
CABACabaletta Bio, Inc.LTM Mar 2026$444K USD-79.7%-20.6%—
BIOABioAge Labs, Inc.LTM Mar 2026$319K USD-59.7%+91.1%3.1%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$296K USD-62.3%-57.9%—
SGHTSight Sciences, Inc.LTM Mar 2026$284K USD+6.0%-38.6%0.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$81K USD-99.8%-43.2%1.0%
Peer median (excluding ACH) —-50.4%-29.6%1.3%

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income221.59M22.39M(41.3M)(362.69M)(102.68M)
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
Deferred Income Tax(29.74M)(26.36M)(23.65M)(26.12M)(17.89M)
Stock-Based Compensation25.02M20.99M23.22M26.84M12.87M
Change in Working Capital(261.4M)89.77M522.29M(25.44M)65.21M
Accounts Receivables(2.2M)1.1M166.58M(94.55M)122.36M
Inventory(263.44M)166.56M224.34M(26.23M)(6.85M)
Accounts Payables3.55M13.65M31M65.19M6.48M
Other Working Capital692K(91.54M)100.37M30.15M(56.78M)
Other Non-Cash Items78.09M(10.45M)(27.22M)284.12M(273.83M)
Operating Cash Flow124.18M325.01M740.71M161.5M(101.79M)
Capital Expenditures(49.69M)(166.58M)(207.89M)(228.16M)(201.33M)
Acquisitions (Net)(43.37M)(1.68B)00324.26M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities39.43M46.71M53.62M94.33M11.12M
Investing Cash Flow(53.63M)(1.8B)(137.25M)(116.53M)144.42M
Debt Repayment(95.35M)1.58B(416.69M)(244.2M)203.5M
Common Stock Issued00000
Common Stock Repurchased0000(10.18M)
Dividends Paid(731K)0000
Other Financing Activities(33.4M)(85.4M)(637K)(23.41M)(5.24M)
Financing Cash Flow(129.48M)1.5B(417.33M)(267.6M)188.08M
Effect of Forex Changes(3.54M)(3.49M)613K(901K)1.9M
Net Change in Cash(62.47M)14.15M186.74M(223.54M)232.61M
Free Cash Flow74.49M158.42M532.82M(66.67M)(303.12M)

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.